secwatch.observer — SEC 8-K summary
======================================

Issuer:     GERON CORP (GERN)
CIK:        0000886744
Form:       8-K
Filed at:   2024-06-07T23:59:59+00:00
Accession:  0000950170-24-070574
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Geron receives FDA approval for RYTELO (imetelstat) in lower-risk MDS with transfusion-dependent anemia
--------------------------------------------------------------------------------

- RYTELO approved for low-to-int-1 risk MDS with TD anemia requiring ≥4 RBC units/8 wks who failed/are ineligible for ESAs.
- Phase 3 IMerge trial: 8-week RBC-TI 39.8% vs 15.0% placebo (p<0.001); 24-week RBC-TI 28.0% vs 3.3% (p<0.001).
- Median RBC-TI duration ~1 year for 8-week responders; ~1.5 years for 24-week responders.
- Most common Grade 3/4 adverse reactions: neutropenia (72%) and thrombocytopenia (65%), each lasting median <2 weeks.
- Conference call with Geron management scheduled for 8am ET on June 7, 2024 to discuss the approval and launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886744/000095017024070574/0000950170-24-070574-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886744/000095017024070574/gern-20240606.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-070574

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer